We are excited to kick off the new year with several funding awards for the development of potential treatments for people living with cystic fibrosis.
- We awarded $5 million BiomX to conduct a Phase 1b/2a clinical trial for a potential phage therapy in Pseudomonas aeruginosa infections.
- To study the potential use of inhaled colistin as an additional option to treat Pseudomonas aeruginosa infections, we awarded $4.7 million to EnBiotix Inc.
- As part of our Path to a Cure initiative, we invested in SalioGen Therapeutics to support preclinical research into a novel genetic therapy that could benefit everyone with cystic fibrosis, regardless of their mutation.
- Finally, we awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in a late phase clinical trial.
Our vision is a cure for every person with cystic fibrosis and a life free from the burden of this disease. We will not leave anyone behind.
